3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
24
Pancreatic Neoplasms
14
Stomach Neoplasms
12
Rectal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
9
Esophageal Neoplasms
9
Colonic Neoplasms
9
Neoplasms
7
Adenocarcinoma Of Esophagus
7
Urinary Bladder Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Cholangiocarcinoma
4
Breast Neoplasms
4
Anus Neoplasms
4
Ovarian Neoplasms
3
Nasopharyngeal Carcinoma
2
Melanoma
2
Hepatoblastoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Clinical Stage I Gastric Cancer AJCC v8
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Urachal cancer
1
Unresectable Colorectal Cancer
1
Interventions
lutetium Lu 177 dotatate
2
pasireotide
1
copper dotatate CU-64
1
amino-acid, glucose, and electrolyte solution
1
abemaciclib
1
Temozolomide
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
E-7386
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
Fluorouracil
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled